Latest Leadership Changes News

Cann Group reported its second-ever quarterly operating cash inflow of $0.24 million in Q4 FY2026, edging closer to cash flow break-even. The company expanded exports to the UK and Germany, launched new products, and completed a leadership transition while redeeming convertible notes and securing additional credit.

BCAL Diagnostics has strengthened its leadership, advanced breast cancer detection tests, and secured key funding and strategic investments to underpin its FY2027 growth plans.

PainChek lifted implemented ARR by 5.9% to $4.46 million and secured its first US commercial contracts under a major Sabra REIT agreement, boosting customer receipts 27% in the June quarter.

Nodestream has advanced its defence strategy with key leadership hires, a $6.5 million capital raise, and fresh product launches, while expanding its footprint in the US and European markets.

Regener8 Resources (ASX:R8R) has finalised its 100% acquisition of the Srebrenica North polymetallic project in Bosnia and Herzegovina, initiated a systematic soil sampling program, and raised $1.415 million through a non-renounceable entitlement offer to fund exploration and working capital.

Greatland Resources (ASX:GGP) exceeded its FY26 production and cost guidance, delivering 329koz of gold at a $2,179/oz AISC and bolstering cash to $1.29 billion. The company advanced key growth projects at Havieron and Telfer, including a major reserve upgrade and promising drilling results at Pinnacles.

Dotz Nano has appointed Nati Harpaz as CEO, introduced Dotz Energy to extend its decarbonisation efforts, and secured $3.3 million in fresh funding to accelerate commercialisation and production scale-up.

ALS Limited reported record FY26 financial results driven by strong growth in Minerals and Industrial Materials, while advancing its digital transformation through the Lab of the Future initiative. Leadership changes and a strategic portfolio review underpin its disciplined capital allocation approach.

6K Additive surged to a record US$7.1 million revenue in Q2 2026, driven by strong demand in critical metal powders and backed by robust cash reserves and government contracts.

ImpediMed reported a 3% revenue increase to $3.6 million in Q4 FY26, bolstered by a $15.3 million capital raise and strategic leadership hires as it pushes growth in cancer survivorship, heart health, and weight management.

Aeeris Ltd has boosted its Annual Recurring Revenue by 9.1% year-on-year to $3.84 million, driven by an 18.6% rise in fixed subscription revenue and a strategic shift towards enterprise clients.

Arovella Therapeutics secured ethics approval and manufactured its first clinical batch of ALA-101, targeting blood cancers, while progressing its solid tumour program and refining autoimmune strategies. The company ended the quarter with $14.4 million in cash, supporting imminent clinical milestones.